Review



human cd9 alexa fluor 488 conjugated antibody  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    R&D Systems human cd9 alexa fluor 488 conjugated antibody
    Graphical representation of workflow for isolation and characterization of Plasma-derived EVs ( A ). Characterization of isolated EVs through transmission electron microscopy ( B ), Scale bar= 100 nm; and confocal microscopy ( C ), Scale bar= 20 μm. Nanoparticle Analysis (NTA) showing the size distribution of EVs (nm) and particle concentration (particle/ml) ( D ); Western blot of EVs markers <t>(CD9,</t> CD63, CD81, Tsg101) and protein co-isolate (Apolipoprotein-B) where Plasma (P) and F [ – ] = SEC Fractions collected ( E )
    Human Cd9 Alexa Fluor 488 Conjugated Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human cd9 alexa fluor 488 conjugated antibody/product/R&D Systems
    Average 93 stars, based on 6 article reviews
    human cd9 alexa fluor 488 conjugated antibody - by Bioz Stars, 2026-06
    93/100 stars

    Images

    1) Product Images from "Stress-induced alteration of small extracellular vesicles drives amyloid-beta sequestration and exacerbates Alzheimer’s disease pathogenesis"

    Article Title: Stress-induced alteration of small extracellular vesicles drives amyloid-beta sequestration and exacerbates Alzheimer’s disease pathogenesis

    Journal: Alzheimer's Research & Therapy

    doi: 10.1186/s13195-026-02028-1

    Graphical representation of workflow for isolation and characterization of Plasma-derived EVs ( A ). Characterization of isolated EVs through transmission electron microscopy ( B ), Scale bar= 100 nm; and confocal microscopy ( C ), Scale bar= 20 μm. Nanoparticle Analysis (NTA) showing the size distribution of EVs (nm) and particle concentration (particle/ml) ( D ); Western blot of EVs markers (CD9, CD63, CD81, Tsg101) and protein co-isolate (Apolipoprotein-B) where Plasma (P) and F [ – ] = SEC Fractions collected ( E )
    Figure Legend Snippet: Graphical representation of workflow for isolation and characterization of Plasma-derived EVs ( A ). Characterization of isolated EVs through transmission electron microscopy ( B ), Scale bar= 100 nm; and confocal microscopy ( C ), Scale bar= 20 μm. Nanoparticle Analysis (NTA) showing the size distribution of EVs (nm) and particle concentration (particle/ml) ( D ); Western blot of EVs markers (CD9, CD63, CD81, Tsg101) and protein co-isolate (Apolipoprotein-B) where Plasma (P) and F [ – ] = SEC Fractions collected ( E )

    Techniques Used: Isolation, Clinical Proteomics, Derivative Assay, Transmission Assay, Electron Microscopy, Confocal Microscopy, Concentration Assay, Western Blot

    Graphical representation of workflow A . In-vitro assessment of amyloid-β (Unaggregated) and EV association. Imaging was performed at three key stages: Control (Without any stresses), Sonication only, and Sonication and agitation combined. TEM micrograph shows morphological characterization of different Aβ aggregated structures formed in the presence of EVs ( B ), Scale bar= 100 nm; CFM images for respective groups ( C )and Colocalization analysis ( D ) showed maximum PCC in the post-sonication group (PCC = 0.73). Colour yellow is the merged signal of EVs (Green) and Aβ (red). Scale bar= 20 μm. PCC between CD9-Alexa 488 EVs and AβSA-Alexa 647. Control: 0.033 ± 0.005; Sonicated: 0.780 ± 0.046; Sonicated & Agitated: 0.499 ± 0.066 ( n = 3). One-way ANOVA: p < 0.0001 (E)
    Figure Legend Snippet: Graphical representation of workflow A . In-vitro assessment of amyloid-β (Unaggregated) and EV association. Imaging was performed at three key stages: Control (Without any stresses), Sonication only, and Sonication and agitation combined. TEM micrograph shows morphological characterization of different Aβ aggregated structures formed in the presence of EVs ( B ), Scale bar= 100 nm; CFM images for respective groups ( C )and Colocalization analysis ( D ) showed maximum PCC in the post-sonication group (PCC = 0.73). Colour yellow is the merged signal of EVs (Green) and Aβ (red). Scale bar= 20 μm. PCC between CD9-Alexa 488 EVs and AβSA-Alexa 647. Control: 0.033 ± 0.005; Sonicated: 0.780 ± 0.046; Sonicated & Agitated: 0.499 ± 0.066 ( n = 3). One-way ANOVA: p < 0.0001 (E)

    Techniques Used: In Vitro, Imaging, Control, Sonication

    Comparison of interaction between EV and small amyloid-β aggregates ( A ) and big amyloid-β aggregates/Fibrils ( B ) at low temperature 4℃. The TEM, Scale bar= 100 nm;, and CFM micrograph shows the EVs sequestering the SA group as opposed to no association between BA/Fibril B . Graphical representation of workflow C . CFM image showing Alexa-Fluor-488 CD9 (Green) and Alexa-Fluor-647Amyloid-β (Red) signals of: EVs only; Aβ; and EVs and Aβ together D . Scale bar= 20 μm. Fluorescence intensity per cell was measured as Mean Fluorescence intensity/Area of ROI. Each condition included 3 cells per dish with a total of n = 9 cells per group. Statistical analysis using one-way ANOVA (Kruskal–Wallis test) indicated a significant difference ( p < 0.001) E . Cell viability ( F ) 10,000cells/well were seeded and included 4 wells per plate with a total of n = 4. Statistical analysis using one-way ANOVA and multiple comparisons showing a highly significant effect ( p < 0.00001)
    Figure Legend Snippet: Comparison of interaction between EV and small amyloid-β aggregates ( A ) and big amyloid-β aggregates/Fibrils ( B ) at low temperature 4℃. The TEM, Scale bar= 100 nm;, and CFM micrograph shows the EVs sequestering the SA group as opposed to no association between BA/Fibril B . Graphical representation of workflow C . CFM image showing Alexa-Fluor-488 CD9 (Green) and Alexa-Fluor-647Amyloid-β (Red) signals of: EVs only; Aβ; and EVs and Aβ together D . Scale bar= 20 μm. Fluorescence intensity per cell was measured as Mean Fluorescence intensity/Area of ROI. Each condition included 3 cells per dish with a total of n = 9 cells per group. Statistical analysis using one-way ANOVA (Kruskal–Wallis test) indicated a significant difference ( p < 0.001) E . Cell viability ( F ) 10,000cells/well were seeded and included 4 wells per plate with a total of n = 4. Statistical analysis using one-way ANOVA and multiple comparisons showing a highly significant effect ( p < 0.00001)

    Techniques Used: Comparison, Fluorescence

    Graphical representation of workflow A . Immunohistological staining images of APP mouse brain sections with CD9 (EVs) and ThT (plaques) showing typical Amyloid- plaques with discrete CD9 signals ( B ) and respective colocalization coefficient D . In-vitro dual staining experimental images: ( C ) APP mice brain sections immunohistological staining with CD9 (antibody) and ThT stained Aβ. ( n = 3 mice brains) (Scale bar 20 μm; Zeiss Confocal microscope and NIS-Elements BR 4.30.00.64-bit fluorescence microscope). Images were captured at (For ThT; λex = 450 nm and λem = 490 nm. CD9-Rodamine TRITC-conjugated; λex = 550 nm and λem = 570 nm). Scale bar= 20 μm
    Figure Legend Snippet: Graphical representation of workflow A . Immunohistological staining images of APP mouse brain sections with CD9 (EVs) and ThT (plaques) showing typical Amyloid- plaques with discrete CD9 signals ( B ) and respective colocalization coefficient D . In-vitro dual staining experimental images: ( C ) APP mice brain sections immunohistological staining with CD9 (antibody) and ThT stained Aβ. ( n = 3 mice brains) (Scale bar 20 μm; Zeiss Confocal microscope and NIS-Elements BR 4.30.00.64-bit fluorescence microscope). Images were captured at (For ThT; λex = 450 nm and λem = 490 nm. CD9-Rodamine TRITC-conjugated; λex = 550 nm and λem = 570 nm). Scale bar= 20 μm

    Techniques Used: Staining, In Vitro, Microscopy, Fluorescence

    Graphical representation of workflow A . Circulating sEVs derived from Control, MCI and AD patient does not show colocalization signal B . Co-incubation with Aβ SA was performed only for control and AD EVs. Controls sEVs incubated with small amyloid-β aggregates C . AD sEVs, when incubated with small amyloid-β aggregates, colocalize (White arrows) at low temperature 4℃ D . Colour Yellow is the colocalised signal for sEVs (Green)and Aβ (Red). Scale bar= 20 μm. PCC ( E ) between CD9–Alexa Fluor 488 EVs and AβSA-Alexa Fluor 647, calculated using Costes thresholding (FIJI/JACoP). Control EVs: 0.033 ± 0.005; AD EVs: 0.780 ± 0.046 ( n = 3). One-way ANOVA: p < 0.0001. Percentage of AβSA associated with EVs ( F ), Control EVs: 2.87 ± 0.90%; AD EVs: 40.37 ± 1.98% (( n = 3; incubation maintained at 4 °C)). Unpaired t-test: p < 0.0001. AD ( n = 9), MCI ( n = 3), and non-demented controls ( n = 10)
    Figure Legend Snippet: Graphical representation of workflow A . Circulating sEVs derived from Control, MCI and AD patient does not show colocalization signal B . Co-incubation with Aβ SA was performed only for control and AD EVs. Controls sEVs incubated with small amyloid-β aggregates C . AD sEVs, when incubated with small amyloid-β aggregates, colocalize (White arrows) at low temperature 4℃ D . Colour Yellow is the colocalised signal for sEVs (Green)and Aβ (Red). Scale bar= 20 μm. PCC ( E ) between CD9–Alexa Fluor 488 EVs and AβSA-Alexa Fluor 647, calculated using Costes thresholding (FIJI/JACoP). Control EVs: 0.033 ± 0.005; AD EVs: 0.780 ± 0.046 ( n = 3). One-way ANOVA: p < 0.0001. Percentage of AβSA associated with EVs ( F ), Control EVs: 2.87 ± 0.90%; AD EVs: 40.37 ± 1.98% (( n = 3; incubation maintained at 4 °C)). Unpaired t-test: p < 0.0001. AD ( n = 9), MCI ( n = 3), and non-demented controls ( n = 10)

    Techniques Used: Derivative Assay, Control, Incubation



    Similar Products

    94
    Miltenyi Biotec anti cd9 pevio615
    Anti Cd9 Pevio615, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti cd9 pevio615/product/Miltenyi Biotec
    Average 94 stars, based on 1 article reviews
    anti cd9 pevio615 - by Bioz Stars, 2026-06
    94/100 stars
      Buy from Supplier

    93
    R&D Systems human cd9 alexa fluor 488 conjugated antibody
    Graphical representation of workflow for isolation and characterization of Plasma-derived EVs ( A ). Characterization of isolated EVs through transmission electron microscopy ( B ), Scale bar= 100 nm; and confocal microscopy ( C ), Scale bar= 20 μm. Nanoparticle Analysis (NTA) showing the size distribution of EVs (nm) and particle concentration (particle/ml) ( D ); Western blot of EVs markers <t>(CD9,</t> CD63, CD81, Tsg101) and protein co-isolate (Apolipoprotein-B) where Plasma (P) and F [ – ] = SEC Fractions collected ( E )
    Human Cd9 Alexa Fluor 488 Conjugated Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human cd9 alexa fluor 488 conjugated antibody/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    human cd9 alexa fluor 488 conjugated antibody - by Bioz Stars, 2026-06
    93/100 stars
      Buy from Supplier

    93
    R&D Systems alexa fluor 647 anti beta amyloid 1 42 antibody
    Graphical representation of workflow A . In-vitro assessment of amyloid-β (Unaggregated) and EV association. Imaging was performed at three key stages: Control (Without any stresses), Sonication only, and Sonication and agitation combined. TEM micrograph shows morphological characterization of different Aβ aggregated structures formed in the presence of EVs ( B ), Scale bar= 100 nm; CFM images for respective groups ( C )and Colocalization analysis ( D ) showed maximum PCC in the post-sonication group (PCC = 0.73). Colour yellow is the merged signal of EVs (Green) and Aβ (red). Scale bar= 20 μm. PCC between <t>CD9-Alexa</t> 488 EVs and AβSA-Alexa <t>647.</t> Control: 0.033 ± 0.005; Sonicated: 0.780 ± 0.046; Sonicated & Agitated: 0.499 ± 0.066 ( n = 3). One-way ANOVA: p < 0.0001 (E)
    Alexa Fluor 647 Anti Beta Amyloid 1 42 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/alexa fluor 647 anti beta amyloid 1 42 antibody/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    alexa fluor 647 anti beta amyloid 1 42 antibody - by Bioz Stars, 2026-06
    93/100 stars
      Buy from Supplier

    94
    Elabscience Biotechnology pe anti cd9 antibody
    Graphical representation of workflow A . In-vitro assessment of amyloid-β (Unaggregated) and EV association. Imaging was performed at three key stages: Control (Without any stresses), Sonication only, and Sonication and agitation combined. TEM micrograph shows morphological characterization of different Aβ aggregated structures formed in the presence of EVs ( B ), Scale bar= 100 nm; CFM images for respective groups ( C )and Colocalization analysis ( D ) showed maximum PCC in the post-sonication group (PCC = 0.73). Colour yellow is the merged signal of EVs (Green) and Aβ (red). Scale bar= 20 μm. PCC between <t>CD9-Alexa</t> 488 EVs and AβSA-Alexa <t>647.</t> Control: 0.033 ± 0.005; Sonicated: 0.780 ± 0.046; Sonicated & Agitated: 0.499 ± 0.066 ( n = 3). One-way ANOVA: p < 0.0001 (E)
    Pe Anti Cd9 Antibody, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pe anti cd9 antibody/product/Elabscience Biotechnology
    Average 94 stars, based on 1 article reviews
    pe anti cd9 antibody - by Bioz Stars, 2026-06
    94/100 stars
      Buy from Supplier

    94
    Elabscience Biotechnology fitc conjugated mouse anti human cd9
    Graphical representation of workflow A . In-vitro assessment of amyloid-β (Unaggregated) and EV association. Imaging was performed at three key stages: Control (Without any stresses), Sonication only, and Sonication and agitation combined. TEM micrograph shows morphological characterization of different Aβ aggregated structures formed in the presence of EVs ( B ), Scale bar= 100 nm; CFM images for respective groups ( C )and Colocalization analysis ( D ) showed maximum PCC in the post-sonication group (PCC = 0.73). Colour yellow is the merged signal of EVs (Green) and Aβ (red). Scale bar= 20 μm. PCC between <t>CD9-Alexa</t> 488 EVs and AβSA-Alexa <t>647.</t> Control: 0.033 ± 0.005; Sonicated: 0.780 ± 0.046; Sonicated & Agitated: 0.499 ± 0.066 ( n = 3). One-way ANOVA: p < 0.0001 (E)
    Fitc Conjugated Mouse Anti Human Cd9, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fitc conjugated mouse anti human cd9/product/Elabscience Biotechnology
    Average 94 stars, based on 1 article reviews
    fitc conjugated mouse anti human cd9 - by Bioz Stars, 2026-06
    94/100 stars
      Buy from Supplier

    94
    Elabscience Biotechnology fitc conjugated mouse anti human cd81
    Graphical representation of workflow A . In-vitro assessment of amyloid-β (Unaggregated) and EV association. Imaging was performed at three key stages: Control (Without any stresses), Sonication only, and Sonication and agitation combined. TEM micrograph shows morphological characterization of different Aβ aggregated structures formed in the presence of EVs ( B ), Scale bar= 100 nm; CFM images for respective groups ( C )and Colocalization analysis ( D ) showed maximum PCC in the post-sonication group (PCC = 0.73). Colour yellow is the merged signal of EVs (Green) and Aβ (red). Scale bar= 20 μm. PCC between <t>CD9-Alexa</t> 488 EVs and AβSA-Alexa <t>647.</t> Control: 0.033 ± 0.005; Sonicated: 0.780 ± 0.046; Sonicated & Agitated: 0.499 ± 0.066 ( n = 3). One-way ANOVA: p < 0.0001 (E)
    Fitc Conjugated Mouse Anti Human Cd81, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fitc conjugated mouse anti human cd81/product/Elabscience Biotechnology
    Average 94 stars, based on 1 article reviews
    fitc conjugated mouse anti human cd81 - by Bioz Stars, 2026-06
    94/100 stars
      Buy from Supplier

    94
    Miltenyi Biotec tetraspanins cd9 apc
    Graphical representation of workflow A . In-vitro assessment of amyloid-β (Unaggregated) and EV association. Imaging was performed at three key stages: Control (Without any stresses), Sonication only, and Sonication and agitation combined. TEM micrograph shows morphological characterization of different Aβ aggregated structures formed in the presence of EVs ( B ), Scale bar= 100 nm; CFM images for respective groups ( C )and Colocalization analysis ( D ) showed maximum PCC in the post-sonication group (PCC = 0.73). Colour yellow is the merged signal of EVs (Green) and Aβ (red). Scale bar= 20 μm. PCC between <t>CD9-Alexa</t> 488 EVs and AβSA-Alexa <t>647.</t> Control: 0.033 ± 0.005; Sonicated: 0.780 ± 0.046; Sonicated & Agitated: 0.499 ± 0.066 ( n = 3). One-way ANOVA: p < 0.0001 (E)
    Tetraspanins Cd9 Apc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tetraspanins cd9 apc/product/Miltenyi Biotec
    Average 94 stars, based on 1 article reviews
    tetraspanins cd9 apc - by Bioz Stars, 2026-06
    94/100 stars
      Buy from Supplier

    94
    Miltenyi Biotec anti human
    Graphical representation of workflow A . In-vitro assessment of amyloid-β (Unaggregated) and EV association. Imaging was performed at three key stages: Control (Without any stresses), Sonication only, and Sonication and agitation combined. TEM micrograph shows morphological characterization of different Aβ aggregated structures formed in the presence of EVs ( B ), Scale bar= 100 nm; CFM images for respective groups ( C )and Colocalization analysis ( D ) showed maximum PCC in the post-sonication group (PCC = 0.73). Colour yellow is the merged signal of EVs (Green) and Aβ (red). Scale bar= 20 μm. PCC between <t>CD9-Alexa</t> 488 EVs and AβSA-Alexa <t>647.</t> Control: 0.033 ± 0.005; Sonicated: 0.780 ± 0.046; Sonicated & Agitated: 0.499 ± 0.066 ( n = 3). One-way ANOVA: p < 0.0001 (E)
    Anti Human, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti human/product/Miltenyi Biotec
    Average 94 stars, based on 1 article reviews
    anti human - by Bioz Stars, 2026-06
    94/100 stars
      Buy from Supplier

    Image Search Results


    Graphical representation of workflow for isolation and characterization of Plasma-derived EVs ( A ). Characterization of isolated EVs through transmission electron microscopy ( B ), Scale bar= 100 nm; and confocal microscopy ( C ), Scale bar= 20 μm. Nanoparticle Analysis (NTA) showing the size distribution of EVs (nm) and particle concentration (particle/ml) ( D ); Western blot of EVs markers (CD9, CD63, CD81, Tsg101) and protein co-isolate (Apolipoprotein-B) where Plasma (P) and F [ – ] = SEC Fractions collected ( E )

    Journal: Alzheimer's Research & Therapy

    Article Title: Stress-induced alteration of small extracellular vesicles drives amyloid-beta sequestration and exacerbates Alzheimer’s disease pathogenesis

    doi: 10.1186/s13195-026-02028-1

    Figure Lengend Snippet: Graphical representation of workflow for isolation and characterization of Plasma-derived EVs ( A ). Characterization of isolated EVs through transmission electron microscopy ( B ), Scale bar= 100 nm; and confocal microscopy ( C ), Scale bar= 20 μm. Nanoparticle Analysis (NTA) showing the size distribution of EVs (nm) and particle concentration (particle/ml) ( D ); Western blot of EVs markers (CD9, CD63, CD81, Tsg101) and protein co-isolate (Apolipoprotein-B) where Plasma (P) and F [ – ] = SEC Fractions collected ( E )

    Article Snippet: sEVs and Aβ42 suspension was labeled using Human CD9 Alexa Fluor ® 488-conjugated Antibody (R&D systems, FAB1880G) for sEVs and Alexa Fluor ® 647 Anti-beta Amyloid 1–42 antibody [mOC64] (Abcam, ab300742) in final concentration of 2%(v/v) and 0.5%(v/v) of the total suspension respectively. sEVs and the aggregate suspension were incubated for 2 h with both antibodies at 25 °C before mounting on labolene-cleaned glass slides (Blue Star) and covered with 18 mm;10Gms glass covers (Blue Star), and were imaged on Zeiss LSM980 system using the 40X objective.

    Techniques: Isolation, Clinical Proteomics, Derivative Assay, Transmission Assay, Electron Microscopy, Confocal Microscopy, Concentration Assay, Western Blot

    Graphical representation of workflow A . In-vitro assessment of amyloid-β (Unaggregated) and EV association. Imaging was performed at three key stages: Control (Without any stresses), Sonication only, and Sonication and agitation combined. TEM micrograph shows morphological characterization of different Aβ aggregated structures formed in the presence of EVs ( B ), Scale bar= 100 nm; CFM images for respective groups ( C )and Colocalization analysis ( D ) showed maximum PCC in the post-sonication group (PCC = 0.73). Colour yellow is the merged signal of EVs (Green) and Aβ (red). Scale bar= 20 μm. PCC between CD9-Alexa 488 EVs and AβSA-Alexa 647. Control: 0.033 ± 0.005; Sonicated: 0.780 ± 0.046; Sonicated & Agitated: 0.499 ± 0.066 ( n = 3). One-way ANOVA: p < 0.0001 (E)

    Journal: Alzheimer's Research & Therapy

    Article Title: Stress-induced alteration of small extracellular vesicles drives amyloid-beta sequestration and exacerbates Alzheimer’s disease pathogenesis

    doi: 10.1186/s13195-026-02028-1

    Figure Lengend Snippet: Graphical representation of workflow A . In-vitro assessment of amyloid-β (Unaggregated) and EV association. Imaging was performed at three key stages: Control (Without any stresses), Sonication only, and Sonication and agitation combined. TEM micrograph shows morphological characterization of different Aβ aggregated structures formed in the presence of EVs ( B ), Scale bar= 100 nm; CFM images for respective groups ( C )and Colocalization analysis ( D ) showed maximum PCC in the post-sonication group (PCC = 0.73). Colour yellow is the merged signal of EVs (Green) and Aβ (red). Scale bar= 20 μm. PCC between CD9-Alexa 488 EVs and AβSA-Alexa 647. Control: 0.033 ± 0.005; Sonicated: 0.780 ± 0.046; Sonicated & Agitated: 0.499 ± 0.066 ( n = 3). One-way ANOVA: p < 0.0001 (E)

    Article Snippet: sEVs and Aβ42 suspension was labeled using Human CD9 Alexa Fluor ® 488-conjugated Antibody (R&D systems, FAB1880G) for sEVs and Alexa Fluor ® 647 Anti-beta Amyloid 1–42 antibody [mOC64] (Abcam, ab300742) in final concentration of 2%(v/v) and 0.5%(v/v) of the total suspension respectively. sEVs and the aggregate suspension were incubated for 2 h with both antibodies at 25 °C before mounting on labolene-cleaned glass slides (Blue Star) and covered with 18 mm;10Gms glass covers (Blue Star), and were imaged on Zeiss LSM980 system using the 40X objective.

    Techniques: In Vitro, Imaging, Control, Sonication

    Comparison of interaction between EV and small amyloid-β aggregates ( A ) and big amyloid-β aggregates/Fibrils ( B ) at low temperature 4℃. The TEM, Scale bar= 100 nm;, and CFM micrograph shows the EVs sequestering the SA group as opposed to no association between BA/Fibril B . Graphical representation of workflow C . CFM image showing Alexa-Fluor-488 CD9 (Green) and Alexa-Fluor-647Amyloid-β (Red) signals of: EVs only; Aβ; and EVs and Aβ together D . Scale bar= 20 μm. Fluorescence intensity per cell was measured as Mean Fluorescence intensity/Area of ROI. Each condition included 3 cells per dish with a total of n = 9 cells per group. Statistical analysis using one-way ANOVA (Kruskal–Wallis test) indicated a significant difference ( p < 0.001) E . Cell viability ( F ) 10,000cells/well were seeded and included 4 wells per plate with a total of n = 4. Statistical analysis using one-way ANOVA and multiple comparisons showing a highly significant effect ( p < 0.00001)

    Journal: Alzheimer's Research & Therapy

    Article Title: Stress-induced alteration of small extracellular vesicles drives amyloid-beta sequestration and exacerbates Alzheimer’s disease pathogenesis

    doi: 10.1186/s13195-026-02028-1

    Figure Lengend Snippet: Comparison of interaction between EV and small amyloid-β aggregates ( A ) and big amyloid-β aggregates/Fibrils ( B ) at low temperature 4℃. The TEM, Scale bar= 100 nm;, and CFM micrograph shows the EVs sequestering the SA group as opposed to no association between BA/Fibril B . Graphical representation of workflow C . CFM image showing Alexa-Fluor-488 CD9 (Green) and Alexa-Fluor-647Amyloid-β (Red) signals of: EVs only; Aβ; and EVs and Aβ together D . Scale bar= 20 μm. Fluorescence intensity per cell was measured as Mean Fluorescence intensity/Area of ROI. Each condition included 3 cells per dish with a total of n = 9 cells per group. Statistical analysis using one-way ANOVA (Kruskal–Wallis test) indicated a significant difference ( p < 0.001) E . Cell viability ( F ) 10,000cells/well were seeded and included 4 wells per plate with a total of n = 4. Statistical analysis using one-way ANOVA and multiple comparisons showing a highly significant effect ( p < 0.00001)

    Article Snippet: sEVs and Aβ42 suspension was labeled using Human CD9 Alexa Fluor ® 488-conjugated Antibody (R&D systems, FAB1880G) for sEVs and Alexa Fluor ® 647 Anti-beta Amyloid 1–42 antibody [mOC64] (Abcam, ab300742) in final concentration of 2%(v/v) and 0.5%(v/v) of the total suspension respectively. sEVs and the aggregate suspension were incubated for 2 h with both antibodies at 25 °C before mounting on labolene-cleaned glass slides (Blue Star) and covered with 18 mm;10Gms glass covers (Blue Star), and were imaged on Zeiss LSM980 system using the 40X objective.

    Techniques: Comparison, Fluorescence

    Graphical representation of workflow A . Immunohistological staining images of APP mouse brain sections with CD9 (EVs) and ThT (plaques) showing typical Amyloid- plaques with discrete CD9 signals ( B ) and respective colocalization coefficient D . In-vitro dual staining experimental images: ( C ) APP mice brain sections immunohistological staining with CD9 (antibody) and ThT stained Aβ. ( n = 3 mice brains) (Scale bar 20 μm; Zeiss Confocal microscope and NIS-Elements BR 4.30.00.64-bit fluorescence microscope). Images were captured at (For ThT; λex = 450 nm and λem = 490 nm. CD9-Rodamine TRITC-conjugated; λex = 550 nm and λem = 570 nm). Scale bar= 20 μm

    Journal: Alzheimer's Research & Therapy

    Article Title: Stress-induced alteration of small extracellular vesicles drives amyloid-beta sequestration and exacerbates Alzheimer’s disease pathogenesis

    doi: 10.1186/s13195-026-02028-1

    Figure Lengend Snippet: Graphical representation of workflow A . Immunohistological staining images of APP mouse brain sections with CD9 (EVs) and ThT (plaques) showing typical Amyloid- plaques with discrete CD9 signals ( B ) and respective colocalization coefficient D . In-vitro dual staining experimental images: ( C ) APP mice brain sections immunohistological staining with CD9 (antibody) and ThT stained Aβ. ( n = 3 mice brains) (Scale bar 20 μm; Zeiss Confocal microscope and NIS-Elements BR 4.30.00.64-bit fluorescence microscope). Images were captured at (For ThT; λex = 450 nm and λem = 490 nm. CD9-Rodamine TRITC-conjugated; λex = 550 nm and λem = 570 nm). Scale bar= 20 μm

    Article Snippet: sEVs and Aβ42 suspension was labeled using Human CD9 Alexa Fluor ® 488-conjugated Antibody (R&D systems, FAB1880G) for sEVs and Alexa Fluor ® 647 Anti-beta Amyloid 1–42 antibody [mOC64] (Abcam, ab300742) in final concentration of 2%(v/v) and 0.5%(v/v) of the total suspension respectively. sEVs and the aggregate suspension were incubated for 2 h with both antibodies at 25 °C before mounting on labolene-cleaned glass slides (Blue Star) and covered with 18 mm;10Gms glass covers (Blue Star), and were imaged on Zeiss LSM980 system using the 40X objective.

    Techniques: Staining, In Vitro, Microscopy, Fluorescence

    Graphical representation of workflow A . Circulating sEVs derived from Control, MCI and AD patient does not show colocalization signal B . Co-incubation with Aβ SA was performed only for control and AD EVs. Controls sEVs incubated with small amyloid-β aggregates C . AD sEVs, when incubated with small amyloid-β aggregates, colocalize (White arrows) at low temperature 4℃ D . Colour Yellow is the colocalised signal for sEVs (Green)and Aβ (Red). Scale bar= 20 μm. PCC ( E ) between CD9–Alexa Fluor 488 EVs and AβSA-Alexa Fluor 647, calculated using Costes thresholding (FIJI/JACoP). Control EVs: 0.033 ± 0.005; AD EVs: 0.780 ± 0.046 ( n = 3). One-way ANOVA: p < 0.0001. Percentage of AβSA associated with EVs ( F ), Control EVs: 2.87 ± 0.90%; AD EVs: 40.37 ± 1.98% (( n = 3; incubation maintained at 4 °C)). Unpaired t-test: p < 0.0001. AD ( n = 9), MCI ( n = 3), and non-demented controls ( n = 10)

    Journal: Alzheimer's Research & Therapy

    Article Title: Stress-induced alteration of small extracellular vesicles drives amyloid-beta sequestration and exacerbates Alzheimer’s disease pathogenesis

    doi: 10.1186/s13195-026-02028-1

    Figure Lengend Snippet: Graphical representation of workflow A . Circulating sEVs derived from Control, MCI and AD patient does not show colocalization signal B . Co-incubation with Aβ SA was performed only for control and AD EVs. Controls sEVs incubated with small amyloid-β aggregates C . AD sEVs, when incubated with small amyloid-β aggregates, colocalize (White arrows) at low temperature 4℃ D . Colour Yellow is the colocalised signal for sEVs (Green)and Aβ (Red). Scale bar= 20 μm. PCC ( E ) between CD9–Alexa Fluor 488 EVs and AβSA-Alexa Fluor 647, calculated using Costes thresholding (FIJI/JACoP). Control EVs: 0.033 ± 0.005; AD EVs: 0.780 ± 0.046 ( n = 3). One-way ANOVA: p < 0.0001. Percentage of AβSA associated with EVs ( F ), Control EVs: 2.87 ± 0.90%; AD EVs: 40.37 ± 1.98% (( n = 3; incubation maintained at 4 °C)). Unpaired t-test: p < 0.0001. AD ( n = 9), MCI ( n = 3), and non-demented controls ( n = 10)

    Article Snippet: sEVs and Aβ42 suspension was labeled using Human CD9 Alexa Fluor ® 488-conjugated Antibody (R&D systems, FAB1880G) for sEVs and Alexa Fluor ® 647 Anti-beta Amyloid 1–42 antibody [mOC64] (Abcam, ab300742) in final concentration of 2%(v/v) and 0.5%(v/v) of the total suspension respectively. sEVs and the aggregate suspension were incubated for 2 h with both antibodies at 25 °C before mounting on labolene-cleaned glass slides (Blue Star) and covered with 18 mm;10Gms glass covers (Blue Star), and were imaged on Zeiss LSM980 system using the 40X objective.

    Techniques: Derivative Assay, Control, Incubation

    Graphical representation of workflow A . In-vitro assessment of amyloid-β (Unaggregated) and EV association. Imaging was performed at three key stages: Control (Without any stresses), Sonication only, and Sonication and agitation combined. TEM micrograph shows morphological characterization of different Aβ aggregated structures formed in the presence of EVs ( B ), Scale bar= 100 nm; CFM images for respective groups ( C )and Colocalization analysis ( D ) showed maximum PCC in the post-sonication group (PCC = 0.73). Colour yellow is the merged signal of EVs (Green) and Aβ (red). Scale bar= 20 μm. PCC between CD9-Alexa 488 EVs and AβSA-Alexa 647. Control: 0.033 ± 0.005; Sonicated: 0.780 ± 0.046; Sonicated & Agitated: 0.499 ± 0.066 ( n = 3). One-way ANOVA: p < 0.0001 (E)

    Journal: Alzheimer's Research & Therapy

    Article Title: Stress-induced alteration of small extracellular vesicles drives amyloid-beta sequestration and exacerbates Alzheimer’s disease pathogenesis

    doi: 10.1186/s13195-026-02028-1

    Figure Lengend Snippet: Graphical representation of workflow A . In-vitro assessment of amyloid-β (Unaggregated) and EV association. Imaging was performed at three key stages: Control (Without any stresses), Sonication only, and Sonication and agitation combined. TEM micrograph shows morphological characterization of different Aβ aggregated structures formed in the presence of EVs ( B ), Scale bar= 100 nm; CFM images for respective groups ( C )and Colocalization analysis ( D ) showed maximum PCC in the post-sonication group (PCC = 0.73). Colour yellow is the merged signal of EVs (Green) and Aβ (red). Scale bar= 20 μm. PCC between CD9-Alexa 488 EVs and AβSA-Alexa 647. Control: 0.033 ± 0.005; Sonicated: 0.780 ± 0.046; Sonicated & Agitated: 0.499 ± 0.066 ( n = 3). One-way ANOVA: p < 0.0001 (E)

    Article Snippet: sEVs and Aβ42 suspension was labeled using Human CD9 Alexa Fluor ® 488-conjugated Antibody (R&D systems, FAB1880G) for sEVs and Alexa Fluor ® 647 Anti-beta Amyloid 1–42 antibody [mOC64] (Abcam, ab300742) in final concentration of 2%(v/v) and 0.5%(v/v) of the total suspension respectively. sEVs and the aggregate suspension were incubated for 2 h with both antibodies at 25 °C before mounting on labolene-cleaned glass slides (Blue Star) and covered with 18 mm;10Gms glass covers (Blue Star), and were imaged on Zeiss LSM980 system using the 40X objective.

    Techniques: In Vitro, Imaging, Control, Sonication

    Comparison of interaction between EV and small amyloid-β aggregates ( A ) and big amyloid-β aggregates/Fibrils ( B ) at low temperature 4℃. The TEM, Scale bar= 100 nm;, and CFM micrograph shows the EVs sequestering the SA group as opposed to no association between BA/Fibril B . Graphical representation of workflow C . CFM image showing Alexa-Fluor-488 CD9 (Green) and Alexa-Fluor-647Amyloid-β (Red) signals of: EVs only; Aβ; and EVs and Aβ together D . Scale bar= 20 μm. Fluorescence intensity per cell was measured as Mean Fluorescence intensity/Area of ROI. Each condition included 3 cells per dish with a total of n = 9 cells per group. Statistical analysis using one-way ANOVA (Kruskal–Wallis test) indicated a significant difference ( p < 0.001) E . Cell viability ( F ) 10,000cells/well were seeded and included 4 wells per plate with a total of n = 4. Statistical analysis using one-way ANOVA and multiple comparisons showing a highly significant effect ( p < 0.00001)

    Journal: Alzheimer's Research & Therapy

    Article Title: Stress-induced alteration of small extracellular vesicles drives amyloid-beta sequestration and exacerbates Alzheimer’s disease pathogenesis

    doi: 10.1186/s13195-026-02028-1

    Figure Lengend Snippet: Comparison of interaction between EV and small amyloid-β aggregates ( A ) and big amyloid-β aggregates/Fibrils ( B ) at low temperature 4℃. The TEM, Scale bar= 100 nm;, and CFM micrograph shows the EVs sequestering the SA group as opposed to no association between BA/Fibril B . Graphical representation of workflow C . CFM image showing Alexa-Fluor-488 CD9 (Green) and Alexa-Fluor-647Amyloid-β (Red) signals of: EVs only; Aβ; and EVs and Aβ together D . Scale bar= 20 μm. Fluorescence intensity per cell was measured as Mean Fluorescence intensity/Area of ROI. Each condition included 3 cells per dish with a total of n = 9 cells per group. Statistical analysis using one-way ANOVA (Kruskal–Wallis test) indicated a significant difference ( p < 0.001) E . Cell viability ( F ) 10,000cells/well were seeded and included 4 wells per plate with a total of n = 4. Statistical analysis using one-way ANOVA and multiple comparisons showing a highly significant effect ( p < 0.00001)

    Article Snippet: sEVs and Aβ42 suspension was labeled using Human CD9 Alexa Fluor ® 488-conjugated Antibody (R&D systems, FAB1880G) for sEVs and Alexa Fluor ® 647 Anti-beta Amyloid 1–42 antibody [mOC64] (Abcam, ab300742) in final concentration of 2%(v/v) and 0.5%(v/v) of the total suspension respectively. sEVs and the aggregate suspension were incubated for 2 h with both antibodies at 25 °C before mounting on labolene-cleaned glass slides (Blue Star) and covered with 18 mm;10Gms glass covers (Blue Star), and were imaged on Zeiss LSM980 system using the 40X objective.

    Techniques: Comparison, Fluorescence

    Graphical representation of workflow A . Circulating sEVs derived from Control, MCI and AD patient does not show colocalization signal B . Co-incubation with Aβ SA was performed only for control and AD EVs. Controls sEVs incubated with small amyloid-β aggregates C . AD sEVs, when incubated with small amyloid-β aggregates, colocalize (White arrows) at low temperature 4℃ D . Colour Yellow is the colocalised signal for sEVs (Green)and Aβ (Red). Scale bar= 20 μm. PCC ( E ) between CD9–Alexa Fluor 488 EVs and AβSA-Alexa Fluor 647, calculated using Costes thresholding (FIJI/JACoP). Control EVs: 0.033 ± 0.005; AD EVs: 0.780 ± 0.046 ( n = 3). One-way ANOVA: p < 0.0001. Percentage of AβSA associated with EVs ( F ), Control EVs: 2.87 ± 0.90%; AD EVs: 40.37 ± 1.98% (( n = 3; incubation maintained at 4 °C)). Unpaired t-test: p < 0.0001. AD ( n = 9), MCI ( n = 3), and non-demented controls ( n = 10)

    Journal: Alzheimer's Research & Therapy

    Article Title: Stress-induced alteration of small extracellular vesicles drives amyloid-beta sequestration and exacerbates Alzheimer’s disease pathogenesis

    doi: 10.1186/s13195-026-02028-1

    Figure Lengend Snippet: Graphical representation of workflow A . Circulating sEVs derived from Control, MCI and AD patient does not show colocalization signal B . Co-incubation with Aβ SA was performed only for control and AD EVs. Controls sEVs incubated with small amyloid-β aggregates C . AD sEVs, when incubated with small amyloid-β aggregates, colocalize (White arrows) at low temperature 4℃ D . Colour Yellow is the colocalised signal for sEVs (Green)and Aβ (Red). Scale bar= 20 μm. PCC ( E ) between CD9–Alexa Fluor 488 EVs and AβSA-Alexa Fluor 647, calculated using Costes thresholding (FIJI/JACoP). Control EVs: 0.033 ± 0.005; AD EVs: 0.780 ± 0.046 ( n = 3). One-way ANOVA: p < 0.0001. Percentage of AβSA associated with EVs ( F ), Control EVs: 2.87 ± 0.90%; AD EVs: 40.37 ± 1.98% (( n = 3; incubation maintained at 4 °C)). Unpaired t-test: p < 0.0001. AD ( n = 9), MCI ( n = 3), and non-demented controls ( n = 10)

    Article Snippet: sEVs and Aβ42 suspension was labeled using Human CD9 Alexa Fluor ® 488-conjugated Antibody (R&D systems, FAB1880G) for sEVs and Alexa Fluor ® 647 Anti-beta Amyloid 1–42 antibody [mOC64] (Abcam, ab300742) in final concentration of 2%(v/v) and 0.5%(v/v) of the total suspension respectively. sEVs and the aggregate suspension were incubated for 2 h with both antibodies at 25 °C before mounting on labolene-cleaned glass slides (Blue Star) and covered with 18 mm;10Gms glass covers (Blue Star), and were imaged on Zeiss LSM980 system using the 40X objective.

    Techniques: Derivative Assay, Control, Incubation